Eric Lefkofsky, the founder and CEO of Tempus AI, sold 250,000 shares of Class A common stock [1].
This transaction occurs as the Chicago-based healthcare technology company pursues a major expansion. The sale follows the company's recent move to acquire Personalis in a deal valued at $1.5 billion [4].
The disposition was disclosed in a filing reported on July 31 [3]. According to the filing, the sale was executed under a pre-scheduled 10b5-1 trading plan [1]. Such plans allow corporate insiders to sell a predetermined number of shares at a set time to avoid accusations of insider trading.
Lefkofsky's sale reduced his indirect stake in the company by about four percent [1]. Despite the transaction, he retains a significant position in the firm, holding roughly 6.5 million shares [1].
The stock movement comes amid a period of high activity for the company. Tempus AI recently reported second-quarter revenue of $382 million [5]. This financial growth aligns with the firm's broader strategy to integrate advanced AI into healthcare diagnostics and precision medicine.
As the company integrates Personalis, the leadership's equity positions remain a point of interest for investors. The use of a 10b5-1 plan suggests the sale was not a reactive decision based on current market volatility or internal developments, but rather a planned reduction of holdings.
“Eric Lefkofsky, the founder and CEO of Tempus AI, sold 250,000 shares of Class A common stock”
The sale of shares by a CEO often triggers investor concern, but the use of a 10b5-1 trading plan indicates the move was planned in advance. Because Lefkofsky retains approximately 6.5 million shares, his long-term alignment with the company's success remains strong even as Tempus AI spends $1.5 billion to acquire Personalis to scale its technology.
